Effective drug delivery by PEGylated drug conjugates.
暂无分享,去创建一个
Richard B Greenwald | Yun H Choe | Jeffrey McGuire | Charles D Conover | J. McGuire | C. Conover | R. B. Greenwald | Y. H. Choe
[1] M. Holčapek,et al. Synthesis and characterisation of a new amphotericin B-methoxypoly(ethylene glycol) conjugate. , 2001, Bioorganic & medicinal chemistry letters.
[2] M. R. Mejillano,et al. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. , 1992, Journal of medicinal chemistry.
[3] F. Marincola,et al. The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma , 1995, Cancer.
[4] P. Friden,et al. Synthesis, in vitro kinetics, and in vivo studies on protein conjugates of AZT: evaluation as a transport system to increase brain delivery. , 1993, Bioconjugate chemistry.
[5] L. R. Hill,et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Y. Ikada,et al. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. , 1994, Journal of pharmaceutical sciences.
[7] M. Wani,et al. Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. , 1995, Cancer research.
[8] H. Zhao,et al. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds. , 1999, Journal of medicinal chemistry.
[9] J Kopecek,et al. Functionalized semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] for protein modification. , 1998, Bioconjugate chemistry.
[10] Y. Tsutsumi,et al. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent. , 1999, Journal of Pharmacology and Experimental Therapeutics.
[11] H. Zhao,et al. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. , 2000, The Journal of organic chemistry.
[12] K. Janda,et al. Soluble polymer-supported organic synthesis. , 2000, Accounts of chemical research.
[13] J. Chern,et al. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. , 2000, Bioconjugate chemistry.
[14] T. Fife,et al. Intramolecular nucleophilic aminolysis of aliphatic esters. Cyclization of methyl 2-aminomethylbenzoate to phthalimidine. , 1976, Journal of the American Chemical Society.
[15] D. Sackett. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. , 1993, Pharmacology & therapeutics.
[16] E. Greenspan,et al. Response of patients with advanced neoplasms to the intravenous administration of alpha-peltatin. , 1954, Journal of the National Cancer Institute.
[17] D. Bolikal,et al. Highly water soluble taxol derivatives: 2′-polyethyleneglycol esters as potential prodrugs , 1994 .
[18] G. Amidon,et al. Cellular Uptake Mechanism of Amino Acid Ester Prodrugs in Caco-2/hPEPT1 Cells Overexpressing a Human Peptide Transporter , 1998, Pharmaceutical Research.
[19] M. Bentley,et al. Pharmacodynamic and Pharmacokinetic Characterization of Poly(ethylene Glycol) Conjugation to Met-enkephalin Analog [d-pen ]-enkephalin (dpdpe) , 2022 .
[20] R. Riccardi,et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? , 1983, The New England journal of medicine.
[21] H. Maeda,et al. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.
[22] J. DiBaise,et al. Polyethylene glycol induces apoptosis in HT‐29 cells: potential mechanism for chemoprevention of colon cancer , 2001, FEBS letters.
[23] K. Juni,et al. Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5'-terminal with poly(ethylene glycol). , 1995, Biological & pharmaceutical bulletin.
[24] A. Hanauske,et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD) , 1993, Investigational New Drugs.
[25] J. McGuire,et al. Drug delivery systems employing 1,6-elimination: releasable poly(ethylene glycol) conjugates of proteins. , 2001, Bioconjugate chemistry.
[26] M. Potměšil,et al. Camptothecins: from bench research to hospital wards. , 1994, Cancer research.
[27] M. Wilchek,et al. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies , 2000, Cancer Immunology and Immunotherapy.
[28] P. Caliceti,et al. A branched monomethoxypoly(ethylene glycol) for protein modification. , 1995, Bioconjugate chemistry.
[29] Hiroshi Maeda,et al. Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.
[30] S. Haas,et al. Pharmacodynamic and Safety Results of PEG-Hirudin in Healthy Volunteers , 1997, Thrombosis and Haemostasis.
[31] Yoshito Ikada,et al. Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injection , 1997 .
[32] F. Dosio,et al. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[33] S. Smith,et al. Cyclization-activated prodrugs. Basic carbamates of 4-hydroxyanisole. , 1990, Journal of medicinal chemistry.
[34] S. Bernhard,et al. Co-operative Effects of Functional Groups in Peptides. I. Aspartyl-serine Derivatives , 1962 .
[35] M. Hershfield,et al. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. , 1998, Seminars in hematology.
[36] J. Young,et al. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. , 1988, The Journal of biological chemistry.
[37] S Davis,et al. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. , 1981, Clinical and experimental immunology.
[38] C. Gilon,et al. Attachment of drugs to polyethylene glycols , 1983 .
[39] V. Erdmann,et al. Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates. , 1994, Nucleic acids research.
[40] S. Zeuzem,et al. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy , 2001, Expert opinion on investigational drugs.
[41] M. S. Tewart,et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .
[42] F. Davis,et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.
[43] M. Okabe,et al. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[44] Y. Tsutsumi,et al. Amino Acids and Peptides: XXXII: A Bifunctional Poly(Ethylene Glycol) Hybrid of Fibronectin-Related Peptides , 1997 .
[45] A. Repta,et al. N-(acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. I: Kinetics and mechanism of degradation in aqueous solutions , 1987 .
[46] D. Thakker,et al. Prodrugs of anticancer agents , 1996 .
[47] D. Bolikal,et al. HIGHLY WATER SOLUBLE TAXOL DERIVATIVES : 7-POLYETHYLENE GLYCOL CARBAMATES AND CARBONATES , 1995 .
[48] J. M. Harris,et al. Poly(Ethylene Glycol) Chemistry Biotechnical and Biomedical Applications , 1992 .
[49] D. Ranganathan,et al. Synthesis of totally chiral, multiple armed, poly Glu and poly Asp scaffoldings on bifunctional adamantane core , 1997 .
[50] K. Vandegriff,et al. Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. , 1997, Biophysical chemistry.
[51] V. Stella,et al. Prodrugs , 1985, Drugs.
[52] N. Hanai,et al. Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumor specific activation. , 2000, Bioorganic & medicinal chemistry.
[53] J. Malinský,et al. The biological effects of some podophyllin compounds and their dependence on chemical structure. II. , 1957, Journal of the National Cancer Institute.
[54] A. Sartorelli,et al. The pharmacology of prodrugs of 5-fluorouracil and 1-beta-D-arabinofuranosylcytosine. , 1984, Advances in pharmacology and chemotherapy.
[55] I. Constable,et al. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides , 2001, Biomaterials.
[56] J. Gliński,et al. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. , 1989, Journal of medicinal chemistry.
[57] W. Denny,et al. The Design of Selectively‐activated Anti‐cancer Prodrugs for use in Antibody‐directed and Gene‐directed Enzyme‐Prodrug Therapies * , 1998, The Journal of pharmacy and pharmacology.
[58] E. Schacht,et al. The crucial role of spacer groups in macromolecular prodrug design , 1996 .
[59] G. Bonora,et al. Antigene effect in K562 cells of a PEG-conjugated triplex-forming oligonucleotide targeted to the bcr/abl oncogene. , 2002, Biochemistry.
[60] C. Lee,et al. Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. , 1998, Bioorganic & medicinal chemistry.
[61] M. Royzen,et al. Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[62] V. Farina. THE CHEMISTRY AND PHARMACOLOGY OF TAXOL® AND ITS DERIVATIVES , 1995 .
[63] J. Kopeček,et al. Targetable polymeric prodrugs , 1987 .
[64] Yan-Hui Liu,et al. Carboxyalkylated Histidine Is a pH-Dependent Product of Pegylation with SC-PEG , 2001, Pharmaceutical Research.
[65] A. F. Youssef,et al. Synthesis and investigation of N4-substituted cytarabine derivatives as prodrugs. , 1995, Die Pharmazie.
[66] Nandini V. Katre,et al. The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential , 1993 .
[67] D. Kingston,et al. Modified Taxols, 6. Preparation of Water-Soluble Prodrugs of Taxol , 1991 .
[68] C. Conover,et al. Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. , 1998, Anti-cancer drug design.
[69] B. Testa,et al. Design of intramolecularly activated prodrugs. , 1998, Drug metabolism reviews.
[70] Z. Shahrokh,et al. Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity. , 2000, International journal of pharmaceutics.
[71] C. Conover,et al. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. , 1999, Anti-cancer drug design.
[72] A. Jäschke,et al. Site-specific modification of enzymatically synthesized RNA: Transcription initiation and Diels-Alder reaction , 1997 .
[73] T. Ishida,et al. N4-Behenoyl-1-β-d-arabinofuranosylcytosine as a Potential New Antitumor Agent , 1977 .
[74] R B Greenwald,et al. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. , 1996, Journal of medicinal chemistry.
[75] L. Moore,et al. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. , 1993, Journal of medicinal chemistry.
[76] R. B. Greenwald,et al. PEG thiazolidine-2-thione, a novel reagent for facile protein modification: conjugation of bovine hemoglobin. , 1996, Bioconjugate chemistry.
[77] David Putnam,et al. Polymer conjugates with anticancer activity , 1995 .
[78] K. Lee,et al. Antitumor agents LXII: synthesis and biological evaluation of podophyllotoxin esters and related derivatives. , 1983, Journal of pharmaceutical sciences.
[79] R. Ward. The synthesis of lignans and neolignans , 1983 .
[80] C Delgado,et al. The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.
[81] M. Wilchek,et al. Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. , 1978, Journal of the National Cancer Institute.
[82] B. Shin,et al. Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats. , 2000, Chemical & pharmaceutical bulletin.
[83] M. Whitlow,et al. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. , 1999, Bioconjugate chemistry.
[84] D. Wyss,et al. Identification of the major positional isomer of pegylated interferon alpha-2b. , 2000, Biochemistry.
[85] V. Erdmann,et al. Automated incorporation of polyethylene glycol into synthetic oligonucleotides , 1993 .
[86] Z. Yao,et al. Drug delivery of anticancer agents: water soluble 4-poly (ethylene glycol) derivatives of the lignan, podophyllotoxin. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[87] M. Royzen,et al. Anticancer drug delivery systems: N4-acyl poly(ethyleneglycol) prodrugs of ara-C. I. Efficacy in solid tumors. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[88] H. Maeda,et al. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.
[89] N. Kuder,et al. Chemoenzymatic synthesis of N-Ras lipopeptides , 1998 .
[90] J. Kopeček,et al. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. , 1987, Journal of biomedical materials research.
[91] W. Wang,et al. Prodrug approaches to the improved delivery of peptide drugs. , 1999, Current pharmaceutical design.
[92] M. Nucci,et al. The therapeutic value of poly(ethylene glycol)-modified proteins , 1991 .
[93] E. Schacht,et al. Review: Poly(Ethylene Glycol)s with Reactive Endgroups. II. Practical Consideration for the Preparation of Protein-PEG Conjugates , 1996 .
[94] A. Guo,et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. , 1998, Biochemical and biophysical research communications.
[95] A. Multani,et al. Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. , 1997, Anticancer research.
[96] R. Mülhaupt,et al. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. , 1999, Bioorganic & medicinal chemistry.
[97] M. Wall,et al. Camptothecin and taxol: Discovery to clinic , 1998, Medicinal research reviews.
[98] C. Conover,et al. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker , 1998, Cancer Chemotherapy and Pharmacology.
[99] Samuel Zalipsky,et al. Chemistry of polyethylene glycol conjugates with biologically active molecules , 1995 .
[100] P. J. Burck,et al. Crystalline L-Asparaginase from Escherichia coli B , 1969, Science.
[101] F. Van de Werf,et al. Polyethylene Glycol–Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction , 2000, Circulation.
[102] G. Morstyn,et al. Filgrastim (r-metHuG-CSF) in the 21st Century: SD/01 , 2001, Acta Haematologica.
[103] H. Bundgaard. The double prodrug concept and its applications , 1989 .
[104] F. Davis,et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.
[105] J. Katzenellenbogen,et al. A novel connector linkage applicable in prodrug design. , 1981, Journal of medicinal chemistry.
[106] F. Zunino,et al. Anti‐tumor activity of daunorubicin linked to poly‐L‐aspartic acid , 1982, International journal of cancer.
[107] C. Conover,et al. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. , 1996, Journal of medicinal chemistry.
[108] A. Hoffman,et al. Mucoadhesive drug carriers based on complexes of poly(acrylic acid) and PEGylated drugs having hydrolysable PEG-anhydride-drug linkages. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[109] D. Vyas. 3 Paclitaxel (taxol®) formulation and prodrugs , 1995 .
[110] R. Borchardt,et al. Prodrug strategies based on intramolecular cyclization reactions. , 1997, Journal of pharmaceutical sciences.
[111] Lei Xie,et al. Structural and Biologic Characterization of Pegylated Recombinant IFN-α2b , 2001 .